These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19780415)

  • 1. [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].
    Kovac M; Rakićević L; Maslać A; Radojković D
    Vojnosanit Pregl; 2009 Aug; 66(8):617-21. PubMed ID: 19780415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.
    Kovac MK; Maslac AR; Rakicevic LB; Radojkovic DP
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):558-63. PubMed ID: 20581661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
    Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
    Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
    Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
    Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.
    Buzoianu AD; Militaru FC; Vesa SC; Trifa AP; Crişan S
    Blood Cells Mol Dis; 2013 Mar; 50(3):166-70. PubMed ID: 23159639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.
    Krishna Kumar D; Madhan S; Balachander J; Sai Chandran BV; Thamijarassy B; Adithan C
    Thromb Res; 2013 Apr; 131(4):363-7. PubMed ID: 23473641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
    Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
    Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
    Kalpana SR; Bharath G; Manjunath CN; Christopher R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.
    Giansante C; Fiotti N; Altamura N; Pitacco P; Consoloni L; Scardi S; Mazzone C; Grassi G; Pandullo C; Di Lenarda A
    J Thromb Thrombolysis; 2012 Nov; 34(4):506-12. PubMed ID: 22592842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population.
    Harikrishnan S; Koshy L; Subramanian R; Sanjay G; Vineeth CP; Nair AJ; Nair GM; Sudhakaran PR
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S110-S115. PubMed ID: 30595241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
    van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
    Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.